Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

British Medical Journal

Volumn 312, Issue 7047, 1996, Pages 1637-1641

  French, John K ^a   Williams, Barbara F ^a   Hart, Hamish H ^b   Wyatt, Susan ^b   Poole, June E ^c   Ingram, Christine ^d   Ellis, Christopher J ^d   Williams, Miles G ^c   White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

^b NORTH SHORE HOSPITAL   (New Zealand)

^c MIDDLEMORE HOSPITAL   (New Zealand)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORONARY CARE UNIT; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

EID: 0029899396     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.312.7047.1637     Document Type: Article

References (32)

1. Gruppo Italiano per to Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-402.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
3. ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465-71.
4. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: a 12-month follow-up report. N Engl J Med 1985;312:1073-8.
5. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317:850-5.
6. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than-1000 patients. Lancet 1994;343:311-22.
7. Behar S, Abinader E, Caspi A, David D, Flich M, Friedman Y, et al. Frequency of use of thrombolytic therapy in acute myocardial infarction in Israel. Am J Cardiol 1991;68:1291-4.
8. Cragg DR, Friedman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, Timmis GC, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy, Ann Intern Med 1991;115:173-7.
9. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
10. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993;342:891-4.
11. Woods KL, Ketley D. Thrombolysis and acute myocardial infarction. Lancet 1994;343:232-3.
12. Haines A, Jones R. Implementing findings of research. BMJ 1994; 308:1488-92.
13. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 1989;320:817-21.
14. Gruppo Italiano per to Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990;336;65-71.
15. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med 1990;113:949-60.
16. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
17. Ward H, Yudkin JS. Thrombolysis in patients with diabetes: withholding treatment is probably mistaken: patients should be given a choice. BMJ 1995;310:3-4.
18. Barbash GI, White HD, Modan M, Van de Werf F, for Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993;22:707-13.
19. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage. Arch Ophthalmol 1987;105:191-5.
20. Scholz KH, Tebbe U, Herrmann C, Wojcik J, Lingen R, Chemnitius JM, et at. Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarction. Am J Cardiol 1992; 69:724-8.
21. Neches RB, Goldfarb AM, Saviano GJ. Thrombolytic therapy in acute myocardial infarction following prolonged cardiopulmonary resuscitation. Clin Cardiol 1991;14:616-9.
22. Tenaglia AN, Califf RM, Candela RJ, Kereiakes DJ, Berrios E, Young SY, et al. Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. Am J Cardiol 1991;68:1015-9.
23. Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM, et at. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J Am Coll Cardiol 1995;26:1651-6.
24. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the national registry of myocardial infarction. Circulation 1994;90:2103-14.
25. Rustige J, Schiele R, Burczyk U, Koch A, Tebbe U, Senges J, et al. High hospital mortality despite frequent use of thrombolysis in acute myocardial infarction [Abstract]. Eur Heart J 1995;16(suppl):9.
26. Gottlieb S, Hod H, Barbash G, Cohen M, Boyko V, Behar S, et al. National survey on the use of thrombolysis and invasive procedures in acute myocardial infarction in Israel in 1994 [Abstract]. Eur Heart J 1995; 16(suppl):9.
27. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
28. Rossi P, Bolognese L, on behalf of Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol 1991;68:585-92.
29. Simoons ML, Serruys PW, van den Brand M, Bär F, de Zwaan C, Res J, et al. Improved survival after early thrombolysis in acute myocardial infarction: a randomised trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet 1985;ii:578-82.
30. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;i:545-9.
31. Wilcox RG, von der Lippe G, Ollson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activation for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 1988;ii:525-30.
32. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342:767-72.